Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pamela Selema"'
Autor:
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F Liau, Javier P Gisbert
The objective of this non-interventional, observational prospective cohort study (CONNECT-IBD) was to assess the use of CT-P13 (Inflectra®) in the treatment of patients with Crohn’s disease (CD) and ulcerative colitis (UC) in the context of treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9dfe56eecdfe77c76000d4f549a9e01
Autor:
Robin Christensen, Peter C. Taylor, Ruffy Guilatco, Heather Fowler, Boulos Haraoui, Pamela Selema, K. F. Liau, Shahrzad Moosavi, Markus Mueller
Publikováno v:
Rheumatology Advances in Practice
Taylor, P C, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Mueller, M, Liau, K F & Haraoui, B 2021, ' Real-life drug persistence in patients with rheumatic diseases treated with CT-P13 : a prospective observational cohort study (PERSIST) ', Rheumatology advances in practice, vol. 5, no. 2, rkab026 . https://doi.org/10.1093/rap/rkab026
Taylor, P C, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Mueller, M, Liau, K F & Haraoui, B 2021, ' Real-life drug persistence in patients with rheumatic diseases treated with CT-P13 : a prospective observational cohort study (PERSIST) ', Rheumatology advances in practice, vol. 5, no. 2, rkab026 . https://doi.org/10.1093/rap/rkab026
ObjectiveThe aim was to report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with RA, AS or PsA who were biologic naïve or switched from an IFX referen
Autor:
Shahrzad Moosavi, Boulos Haraoui, Heather Fowler, Peter C. Taylor, Claire Bombardier, Ruffy Guilatco, Pamela Selema, Robin Christensen
Publikováno v:
Poster Presentations.
Background CT-P13, an infliximab biosimilar, has been available in Europe and Canada since 2015, and real-world experience with CT-P13 is important to support the safety of this medication. PERSIST is an ongoing, observational cohort study evaluating
Autor:
Bernd Bokemeyer, M J Cadatal, Javier P. Gisbert, Heather Fowler, Matthieu Allez, Shahrzad Moosavi, Raymond Cheung, Pamela Selema, Milan Lukas, Tibor Hlavaty
Publikováno v:
Journal of Crohn's and Colitis. 13:S410-S410